REVIEW article

Front. Pharmacol., 23 November 2021

Sec. Integrative and Regenerative Pharmacology

Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.772678

Recent Advances in Pharmacological Intervention of Osteoarthritis: A Biological Aspect

  • 1. Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang, China

  • 2. College of Dentistry, Yonsei University, Seoul, South Korea

  • 3. Department of Stomatology, Guangdong Medical University, Zhanjiang, China

Article metrics

View details

12

Citations

5,8k

Views

2,6k

Downloads

Abstract

Osteoarthritis (OA) is a degenerative joint disease in the musculoskeletal system with a relatively high incidence and disability rate in the elderly. It is characterized by the degradation of articular cartilage, inflammation of the synovial membrane, and abnormal structure in the periarticular and subchondral bones. Although progress has been made in uncovering the molecular mechanism, the etiology of OA is still complicated and unclear. Nevertheless, there is no treatment method that can effectively prevent or reverse the deterioration of cartilage and bone structure. In recent years, in the field of pharmacology, research focus has shifted to disease prevention and early treatment rather than disease modification in OA. Biologic agents become more and more attractive as their direct or indirect intervention effects on the initiation or development of OA. In this review, we will discuss a wide spectrum of biologic agents ranging from DNA, noncoding RNA, exosome, platelet-rich plasma (PRP), to protein. We searched for key words such as OA, DNA, gene, RNA, exosome, PRP, protein, and so on. From the pharmacological aspect, stem cell therapy is a very special technique, which is not included in this review. The literatures ranging from January 2016 to August 2021 were included and summarized. In this review, we aim to help readers have a complete and precise understanding of the current pharmacological research progress in the intervention of OA from the biological aspect and provide an indication for the future translational studies.

Introduction

Osteoarthritis (OA) is a degenerative chronic joint disease mainly affects the elderly, causing pain and loss of movement function. The trends of an aging population worldwide and increasing obesity are likely to make OA a leading cause of disability in the elderly (Hunter et al., 2020). Although many risk factors such as abnormal joint biomechanics, bone-mass index, joint injury, and genetic variations have been identified in the causation of OA, the etiology of OA is still poorly understood. In a traditional point of view, cartilage degradation was purely caused by mechanical imbalance (Francisco et al., 2018). Currently, increasing evidence shows that OA is a complex condition, in which the whole joints, including cartilage, subchondral bone, and synovium probably, are all involved in the pathogenesis (Goldring and Goldring, 2016), among which degradation of cartilage caused by matrix proteases plays a pivotal role (Pérez-García et al., 2019). In general, OA is a disease resulting from an imbalance between catabolic and anabolic events. In recent years, biologic agents become more and more attractive as they either target specific catabolic events, such as inflammation or matrix degradation, or promote anabolic events, such as anti-inflammation or chondrogenesis. In this review, we provide an update of the current treatment strategies and recent research progress in the pharmacological intervention of OA from the biology aspect (Figure 1).

FIGURE 1

Methods

We searched PubMed for combination of the following indexed subject headings [MeSH]: osteoarthritis, DNA, noncoding RNAs, exosomes, platelet-rich plasma, and proteins.

Current Treatment Strategies

Clinical management for OA patients depends on their development stages of the disease. As the pathogenesis of OA is complicated, there is still no specific intervention for the treatment of OA. The primary goal for OA management is to alleviate pain and stiffness and maintain the joint function (Hermann et al., 2018). The treatment strategies for OA can be divided into three categories: nonpharmacological interventions, pharmacological interventions, and surgical interventions. Current consensus guidelines recommend the use of combination of nonpharmacological interventions, pharmacological interventions, and surgical intervention where necessary. The majority of individuals with OA can be managed successfully with a combination of nonpharmacological interventions and pharmacological interventions. However, surgical approaches should be considered at the late stages to repair the cartilage lesions or even replace the joint to regain the function.

Lifestyle modification and physical therapy are the two main nonpharmacological interventions. Body weight control in obese patients improves the symptoms and reduces the risk of symptomatic OA will develop. Exercise strengthens the muscle around the joints and maintain the stability. Physical therapy, such as pulsed electromagnetic fields (Yang et al., 2018a), extracorporeal shock wave therapy (ESWT) (Yu et al., 2017), acupuncture (Tu et al., 2021), and so on, improves the mobility and relieves the symptoms. Chondroitin sulfate and glucosamine have been used as dietary supplements.

Nonpharmacological interventions could be insufficient for many patients who develop symptomatic OA. Pharmaceutical agents, especially acetaminophen and nonsteroidal anti-inflammatory drugs, play a key role in symptom control. Other agents such as duloxetine (Weng et al., 2020), opioids, intra-articular steroid (Wijn et al., 2020), and viscosupplement injections are also approved for OA management. These drugs may effectively relieve the pain. However, many safety concerns have been raised regarding their side effects.

Surgical interventions are inevitable for many patients. Joint reservation surgeries, such as high tibial osteotomy and joint distraction, have shown symptomatic improvement (van der Woude et al., 2017). However, evidence for the long-term effectiveness is still to be confirmed. Unicompartmental knee arthroplasty (Murray and Parkinson, 2018), total knee arthroplasty (TKA) (Gademan et al., 2016), and total hip arthroplasty are widely accepted by the patients with end-stage OA.

Recent Progress in Biological Interventions

DNA- or Gene-Based Therapy

DNA (Minchin and Lodge, 2019) is a double-stranded and long-chain polymer composed of four deoxynucleotides. DNA fragments with genetic information are called genes. At present, many genes are reported to be related to the occurrence and development of OA by increasing susceptibility, enhancing cartilaginous matrix degradation, preventing cartilage from repair, increasing the expression of inflammatory factors, or promoting fibroblast transformation. First, the susceptibility genes of OA mainly include ASPN (Wang et al., 2018), ADIPOQ (Shang et al., 2019), AKNA (Zhao et al., 2020a), DPEP1 (Zhang et al., 2021a), rs1065080 (Lu et al., 2019a), TLR7 (Wang et al., 2020a), RTP4 (Wang et al., 2020a), CRIP1 (Wang et al., 2020a), ZNF688 (Wang et al., 2020a), TOP1 (Wang et al., 2020a), EIF1AY (Wang et al., 2020a), RAB2A (Wang et al., 2020a), ZNF281 (Wang et al., 2020a), UIMC1 (Wang et al., 2020a), and PRKACB (Zhao, 2021). Second, the genes that promote the degradation of cartilage mainly include ADAMTS5 (Jiang et al., 2021), ADAM12 (Lv et al., 2017), JUN (Rhee et al., 2017), PTGS2 (Zhou et al., 2019a), MMP1 (Zhou et al., 2019a), MMP3 (Zhou et al., 2019a), MMP13 (Zhou et al., 2019a), AGT (Wang et al., 2020b), and rs2830585 (Zhou et al., 2019b). Third, several genes such as BMP3 (He et al., 2018), rs1799750 (Geng et al., 2018), and CHI3L1 (Song et al., 2021) show an inhibitory effect on cartilage repair. Fourth, the genes that regulate the expression of inflammatory cytokines in chondrocytes mainly include renin (Wu et al., 2019a), ACE (Wu et al., 2019a), Ang II (Wu et al., 2019a), AT1R (Wu et al., 2019a), AT2R (Wu et al., 2019a), ATF3 (Iezaki et al., 2016), PTGS2 (Lin et al., 2018; Wang et al., 2020a), CCL20 (Lin et al., 2018), CHI3L1 (Lin et al., 2018), LIF (Lin et al., 2018), CXCL8 (Lin et al., 2018), and CXCL12 (Lin et al., 2018). Last but not least, COL6A3/ACTG1 (Li et al., 2020a) and fibronectin1 (FN1) (Wu et al., 2020a) were found involved in fibroblast transformation. Although many catabolic genes have been found, there are very limited key anabolic genes that can promote the proliferation or differentiation of chondrocytes or encode key anchoring collagen molecules and the corresponding genes including GDF5 (Sun et al., 2021), Gas7 (Zhong et al., 2020), PRELP (Li et al., 2019a), TGF-β (Tao et al., 2016), SOX9 (Tao et al., 2016), and COL9A1 (Durand et al., 2020).

Genetic modification of joints has been achieved in preclinical models by ex vivo and in vivo strategies using a variety of vectors (Evans et al., 2018). Delivering genes from the body to the joints through direct intra-articular injection is a feasible way to speed up treatment. However, many vectors are inflammatory, immunogenic, or unsafe or provide only short-term transgene expression after successfully transferring cells into joint tissues. In order to solve this problem, an ideal delivery vector in vivo has been discovered; it is the adeno-associated virus (AAV), which is safer, more effective, and less immunogenic than other vectors (Evans et al., 2018). In addition, AAV also prolongs the expression time of transgenes in joints. When injected into the joint, the recombinant AAV will transduce synovial lining cells and chondrocytes at the thickness of the articular cartilage (Watson Levings et al., 2018). Besides the genetic regulation, epigenetic regulations, such as DNA methylation, may be also involved in OA pathology. Hypermethylation leads to a decrease in the expression of COL9A1, destroys the integrity of cartilage, and promotes the development of OA (Miranda-Duarte, 2018). SOX9 is a key transcription factor for cartilage formation in chondrocytes. The DNA methylation of SOX9 gene promoter in chondrocytes of patients with OA increases. This increase in methylation reduces the binding affinity of transcription factors, thereby reducing the expression of SOX9 in OA chondrocytes (He et al., 2020a). The DNA methyltransferases could be the potential targets to the treatment of OA in the future.

Noncoding RNA-Based Therapy

As mentioned, many studies in OA have focused on the epigenetic regulation of its pathogenesis and potential targets for therapy, specifically noncoding RNA (ncRNA). Human genome is estimated to contain ∼2% protein-coding RNA, whereas a vast majority of the genome comprises ncRNA. These ncRNAs, such as microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA), are involved in the pathological development of OA, which can be used as diagnostic and therapeutic markers for OA progression and prognosis. Recent preclinical evidence shows that many ncRNAs can directly affect the expression of key genes involved in OA, which have great translational potential in OA treatment (Duan et al., 2020). Future research on elucidating the role of ncRNAs will also help in better understanding the etiology of OA. In particular, research and development of therapeutic targets for OA provide important clues (Cong et al., 2017). However, studies also report that many ncRNAs are considered the critical elements in cancer development (He et al., 2021a). Sufficient preclinical safety inspections should be performed before clinical use (Xie et al., 2020a).

MiRNA

Among those ncRNAs, miRNAs are most popular in recent years, with approximately 22 nucleotides, functioning in RNA silencing and posttranscriptional regulation of gene expression. Many studies have reported that several miRNAs could play an important role in regulating bone and cartilage homeostasis (Shen et al., 2019) (Table 1), through regulating the signaling pathways involved in extracellular matrix (ECM) degradation, apoptosis or hypotrophy of chondrocytes, or synovial inflammation.

TABLE 1

FunctionsEffectsMiRNAsTargetsReferences
Negative regulationInhibit chondrocyte proliferationmiR-21GDF-5Sekar (2021)
Promote osteoclast formationmiR-21UnknownSekar (2021)
Promote chondrocyte apoptosismiR-146aSMAD4Malemud (2018)
miR-1236PIK3R3Wang et al. (2020c)
miR-34aVisfatin (NF-ΚB)/ADAMTS-4Cheleschi et al. (2019)
miR-181aGPD1LZhai et al. (2017)
MiR-155GPD1LZhai et al. (2017)
miR-384-5pSOX9Zhang et al. (2018a)
miR-9Sirtuin-1D'Adamo et al. (2017)
miR-335-5PHBP1Lu et al. (2021)
miR-107TRAF3Zhao et al. (2019)
Promote inflammationmiR-149-5pAGTWang et al. (2020b)
Increase matrix degradationmiR-33aTGF-β1/Akt/SREBP-2Ghafouri-Fard et al. (2021)
miR-483-5pHDAC4, Matn3/Timp2Wang et al. (2019a)
miR-101SOX9Chu et al. (2019)
Promote cartilage degradationmiR-141/200cSIRT1Ji et al. (2020a)
miRNA 218-5pPIK3C2ALu et al. (2017)
miR-146bAlpha-2-macroglobulin (A2M)/SOX5Liu et al. (2019b)
miR-21-5pFGF18Wang et al. (2019b)
miR-98Bcl-2Wang et al. (2017b)
Inhibit chondrocyte differentiationmiR-582-5pRunx2Wang et al. (2019c)
miR-324-5pGLI1 and SMOWoods et al. (2019)
Positive regulationPromote chondrocyte proliferationmiR-132PTEN/PI3K/AKTZhang et al. (2021c)
miR29aMMP-13/ADAMTS-5Komori (2016)
miR-138NEK2Xu et al. (2019)
miR-4784Col2a1/MMP-3Liu et al. (2018)
miR-210HIF-3αZhao et al. (2020c)
miR-101Sox9/Runx2Gao et al. (2019)
miR-210-3pSOX9/COLIIYang et al. (2021b)
Promote cartilage regenerationmiR-149-5pFUT-1Çelik et al. (2019)
Inhibit chondrocyte apoptosismiR-766-3PAIFM1Li et al. (2020b)
miR-132PTEN/PI3K/AKTZhang et al. (2021c)
miR-582-3pYAP1He et al. (2020b)
miR-455-3pPI3K/AKTWen et al. (2020)
miR-138NEK2Xu et al. (2019)
miR-93-5pTCF4Xue et al. (2019)
Repression of chondrocyte autophagymiR-130aHOTAIR lncRNAHu et al. (2019)
Inhibit osteoclast formationmiR-125bUnknownYoshiko and Minamizaki (2020)
Inhibit the degradation of cartilagemiR-221SDF1/CXCR4Zheng et al. (2017)
Decrease metabolic enzyme activitymiR-1FZD7Xie et al. (2020a)
Suppress inflammationmiR-582-3pYAP1He et al. (2020b)
miR-335-5p3-MAZhong et al. (2019)
miR-106a5pGLIS3Ji et al. (2018)
Inhibit ECM degradationmiR-582-3pYAP1He et al. (2020b)
miRNA-140MMP-13/ADAMTS-5Si et al. (2017)
miR-145MKK4Hu et al. (2017)
Enhance cartilage repairmi-107HMGB-1Lin et al. (2019)
Inhibit the destruction of articular cartilagemiR-204Runx2Huang et al. (2019a)

miRNA and the targets in osteoarthritis.

LncRNA

lncRNAs are another type of ncRNAs that are longer than 200 nucleotides (Zhang et al., 2021b). LncRNA–RNA interaction controls mRNA translation and degradation, or as silent miRNA sponges. They are also regarded as important regulators of cartilage development (Table 2). The anti-OA mechanism of lncRNA may be achieved by competitively binding miRNA, reducing the binding of miRNA and downstream genes, and increasing the transcription and expression of downstream genes (Wu et al., 2019b).

TABLE 2

FunctionsRNAsTargetReferences
Negative regulationMIAImiR-132Li et al. (2019b)
DANCRmiR-216a-5p/JAK2Zhang et al. (2018b)
TM1P3miR-22Li et al. (2019c)
CTD-2574D22.4UnknownLi et al. (2019d)
CAIFmiR-1246Qi et al. (2019)
TNDSF10miR-376-3p/FGFR1Huang et al. (2019b)
LOC101928134IFNA1Yang et al. (2019a)
CASA2UnknownHuang et al. (2019c)
CHRFmicroRNA-146aYu et al. (2019)
NespasmiR-291a-3pPark et al. (2019)
H19miR-130aHu et al. (2019)
THRILmicroRNA-125bLiu et al. (2019c)
TUGmiR-195Tang et al. (2018)
P21miR-130bHan and Liu (2018)
CIRmiR-27Li et al. (2017a)
PVT1miR-488-3pLi et al. (2017b)
XISTmiR-211Li et al. (2018a)
MBNL1-AS1KCNMA1Li et al. (2018b)
HOTAIRmiR-17-5pHu et al. (2018)
miR-130a-3pHe and Jiang (2020)
FAS-AS1MMP1/MMP13/COL2A1Zhu et al. (2018)
TMSB4miRNA-152Liu et al. (2016)
HOTTIPUnknownHe et al. (2021b)
LINC02288miR-374a-3pFu et al. (2021)
LINC01534miR140-5pWei et al. (2019)
MSRmiR-152Liu et al. (2016)
PART1miR-373-3p/SOX4Zhu and Jiang (2019)
GAS5miR-34a/Bcl-2Ji et al. (2020b)
NEAT1miR-193a-3p/SOX5Liu et al. (2020)
Positive regulationFOXD2-AS1miR-27a-3pWang et al. (2019d)
miR-206Cao et al. (2018)
ANCRTGF-β1Li et al. (2019e)
ANRILmiR-122-5p/DUSP4Li et al. (2019f)
DILCIL-6Huang et al. (2019d)
DNM3OSmiR-126/IGF1Ai and Yu (2019)
MIR4435-2HGUnknownXiao et al. (2019a)
SNHG1MAPK/NF-κBLei et al. (2019)
HULCmiR-101Chu et al. (2019)
HOTAIRM1-1miR-125b/BMPR2Xiao et al. (2019b)
PACERUnknownJiang et al. (2019)
PART1miR-590-3p/TGFBR2/SMAD3Lu et al. (2019b)
MEG3miR-93Chen et al. (2019)
miR-16Xu and Xu (2017)
LINC00341miR-141Yang et al. (2019b)
ATBmiR-223Ying et al. (2019)
PMS2L2miR-203Li et al. (2019g)
MALAT1miR-150-5pZhang et al. (2019)
RORHIF1α/p53Yang et al. (2018b)
ZFAS1Wnt3aYe et al. (2018)
GACAT3IL-6/STAT3Li et al. (2018c)
UFC1miR-34aZhang et al. (2016)
NKILAmiR-145/SP1/NFκBXue et al. (2020)

lncRNAs and the targets in osteoarthritis.

CircRNA

CircRNA is a covalently closed circRNA molecule that contains exon sequences and is spliced at the canonical splicing site (Tam et al., 2019), functioning as miRNA sponges or competing endogenous RNAs that naturally sequester and competitively inhibit miRNA activity. CircRNAs also emerge as a new player in the development of OA through mechanisms such as interfering chondrocyte proliferation and apoptosis, regulating ECM degradation, and inflammation (Yang et al., 2020) (Table 3).

TABLE 3

FunctionsRNAsTargetReferences
Negative regulationCircRNA-UBE2G1miR-373/HIF-1aChen et al. (2020a)
Circ_0136474miR-127-5p/MMP-13Li et al. (2019h)
CircPSM3miRNA-296-5pNi et al. (2020b)
has_Circ_0005105miR-26a/NAMPTWu et al. (2017b)
hsa_Circ_0032131unknownWang et al. (2019e)
hsa_Circ_0104873UnknownYu et al. (2018)
hsa_Circ_0104595
hsa_Circ_0101251
CircRNA-CDR1asmiR-641/FGF-2Zhang et al. (2020)
CircRNA_Atp9bmiR-138-5pZhou et al. (2018)
CircRNA.33186miR-127-5p/MMP-13Zhou et al. (2019c)
CircGCN1L1miR-330-3p/TNF-αZhu et al. (2020)
Circ-SERPINE2miR-1271/ERGTam et al. (2019)
CiRS-7miR-7Zhou et al. (2019d)
CircHYBIDmiR-29b-3p/TGF-β1Liao et al. (2021)
Circ-SPG11miR-337-3p/ADAMTS5Liu et al. (2021)
Circ-CSNK1G1miR-4428/FUT2Xiao et al. (2021)
Positive regulationCircVCANNF-κBMa et al. (2020)
Circ9119miR-26a/PTEN,Chen et al. (2020b)
hsa_Circ_0045714miR-193b/IGF-1RLi et al. (2017c)
hsa_Circ_0020014UnknownWang et al. (2020d)
CircPDE4DmiR-103a-3p/FGF18Wu et al. (2021)

CircRNAs and the targets in osteoarthritis.

Protein-Based Therapy

The protein currently used in clinical practice is mainly platelet-rich plasma (PRP) (Szwedowski et al., 2021). PRP is an autologous plasma preparation rich in platelets whose plasma concentration is higher than the normal concentration in whole blood. The basic principle of therapeutic potential of high-concentration platelets is based on their ability to provide superphysiological amounts of essential growth factors to provide regenerative stimulation that can promote tissue repair. PRP preparations need to be activated before use (Gentile et al., 2020). Intra-articular injections of PRP may be an effective alternative treatment to pain killers for knee OA (Rajan et al., 2020). It significantly promoted the proliferation of chondrocytes, decreased apoptosis, and increased autophagy by regulating the markers including FOXO1, FOXO3, and HIF-1 in osteoarthritic chondrocytes (Moussa et al., 2017). The concentration of white blood cells during the leukocyte-rich PRP (LR-PRP) preparation will affect its efficacy (Yaşar Şirin et al., 2017). It is reported that compared with the LR-PRP, the leukocyte-poor PRP (LP-PRP) has an effect on improving the proliferation of chondrocytes. The lubricating property of hyaluronic acid (HA) facilitates the movement of joints. And a combination of HA and PRP (HA–PRP) (Zhao et al., 2020b) could exert a beneficial synergistic effect for OA treatment. However, up until now, the preparation method and the components of PRP have still not been standardized, making the efficacy of PRP therapy to be inconclusive.

In addition to PRP, the proteins currently studied include nerve growth factor antibody (Grässel and Muschter, 2020) or its antagonists (Denk et al., 2017), fibroblast growth factor (FGF) (Xie et al., 2020b), insulin-like growth factor–binding proteins (IGFBP) (Tanaka et al., 2021), growth and differentiation factor 5 (Kania et al., 2020), Wnt16 (Tong et al., 2019), low-density lipoprotein receptor–related protein 5 (Wu et al., 2017a), neuropeptide Y (NPY) (Kang et al., 2020), and so on. Among the proteins, fasinumab (Dakin et al., 2020), tanezumab (Berenbaum et al., 2020), sprifermin (Eckstein et al., 2020), teriparatide (Apostu et al., 2019), and so on, have shown various effects on the management of OA in clinical trials. Nerve factor antibodies and their antagonists, fasinumab and tanezumab, can improve pain, and the antagonists have the most significant effect. Tanezumab can easily lead to rapidly progressive OA. FGF, GDF5, Wnt16, NPY, sprifermin, and teriparatide are related to cartilage repair. IGFBP is related to cartilage matrix synthesis. The binding of low-density lipoprotein receptor–related protein and sclerostin can inhibit the degradation of normal chondrocytes, but it does not seem to have such an effect in OA. The specific reason is not clear.

Recently, histone modifications have been recognized as another important epigenetic regulation in OA-related genes. LSD1 KDM4B, KDM6A, KDM6B, EZH2, and DOT1L were reported to be the major epigenetic regulators in OA onset and progression through their methyltransferases and demethylase activities by binding to the OA-related gene (e.g., Runx2, Nfat1, and Sox9) promoters or by interplaying with OA-associated signaling transduction pathways (Sacks et al., 2018). Modified histone domains have thus become epigenetic signatures, which will either mark for gene activation or gene repression. The role of methyltransferases and demethylase in epigenetic regulations also indicate they could be potential targets for the management of OA.

Exosomes

Exosomes are small, single-membrane, secreted organelles with a diameter of approximately 30–200 nm. They have the same topological structure as cells and are rich in selected proteins, lipids, nucleic acids, and glycoconjugates (Pegtel and Gould, 2019). Exosomes mainly mediate cell–cell communication through direct membrane fusion or protein–protein interaction (Wu et al., 2020b). The source of exosomes comes in many forms (Ni et al., 2020a), including peripheral blood (Chang et al., 2018), synovial fluid (Gao et al., 2020), mesenchymal stem cells (Tofiño-Vian et al., 2018), embryonic stem cells (Wang et al., 2017a), vascular endothelial cells (Yang et al., 2021a), dental pulp stem cells (Lin et al., 2021), monocytes (Bai et al., 2020), amniotic fluid stem cells (Beretti et al., 2018), chondrogenic progenitor cells (Toh et al., 2017), chondrocytes (Zheng et al., 2019), PRP (Liu et al., 2019a), osteocytes (Lyu et al., 2020) (Table 4), and so on. Exosomes with different origins may have different functions. Exosomes in the joint microenvironment are involved in the development of OA. Most therapeutic exosomes may have an anabolic effect by promoting expression of chondrogenic markers or cartilage ECM or exert an effect by inhibiting inflammation, hypertrophy, or apoptosis of chondrocytes (Zhou et al., 2020) showing great potential for OA therapy.

TABLE 4

FunctionsOriginsMechanisms
Catabolic effectSynovial fluid (Gao et al., 2020), vascular endothelial cells (Yang et al., 2021a)Recruit inflammatory cells (Gao et al., 2020), inhibit cartilage proliferation (Gao et al., 2020), promote joint degeneration (Gao et al., 2020), or induce chondrocyte apoptosis (Yang et al., 2021a)
Anabolic effectMesenchymal stem cells (Tofiño-Vian et al., 2018), embryonic stem cells (Wang et al., 2017a), dental pulp stem cells (Lin et al., 2021), monocyte (Bai et al., 2020), amniotic fluid stem cells (Beretti et al., 2018), chondrogenic progenitor cells (Toh et al., 2017), chondrocytes (Zheng et al., 2019), platelet-rich plasma (Liu et al., 2019a), osteocytes (Lyu et al., 2020)Reduce production of catabolic enzymes (Tofiño-Vian et al., 2018), promote chondrocytes to express cartilage ECM (Wang et al., 2017a; Kim et al., 2020; Guillén et al., 2021), promote chondrocyte differentiation (Bai et al., 2020), promote proliferation of chondrocytes (Liu et al., 2019a; Lyu et al., 2020), inhibit chondrocyte apoptosis (Liu et al., 2019a; Lyu et al., 2020; Lin et al., 2021), regulate immune response (Zheng et al., 2019), or inhibit expression of inflammatory cytokines (Toh et al., 2017; Beretti et al., 2018; Tofiño-Vian et al., 2018; Kim et al., 2020; Qiu et al., 2021)

Exosomes in the treatment of OA.

Sustained-release drug delivery systems have been developed by a combination of exosomes and tissue engineering strategies, showing great promising results in recent research by delivering targeted drug or nucleic acids for regenerative medicine (Akbari et al., 2020). However, because of complexity in the components and rare understanding of their functions, exosomes remain challenges for clinical applications (Zhou et al., 2020).

Literature Analysis

In order to analyze the research trends in the field of OA treatment using the biologic agent in recent years, we have reviewed relevant literature on DNA, RNA, protein, and exosome in the past 5 years on PubMed and also subdivided RNA into circRNA, lncRNA, and miRNA. We present a graphic (Figure 2) and the corresponding table (Supplementary Table S1) to show the literature trend in the past 5 years from January 2016 to August 2021. From the results, we can see that the number of articles of each type of biological agent has increased throughout the past 5 years. Among the four types of biologic agents, the most abundant research on proteins was found, followed by RNA, then DNA, and finally exosomes. Within RNA, miRNA has been studied most intensively, followed by lncRNA, and finally circRNA. This result shows that the research on proteins and RNA is relatively mature, but DNA and exosomes are new highlights in recent years. Within RNA, there are relatively many studies on miRNA and relatively fewer studies on lncRNA and circRNA. Therefore, DNA, exosomes, lncRNA, and circRNA may all become new research hotspots.

FIGURE 2

Discussion

DNA, RNA, and protein described in this article have shown various regulatory effects on the pathological process of OA. Some of those are expected to become targets in terms of diagnosis and treatment of OA. In general, the effects of biologic agents are divided into two aspects: catabolic or anabolic effect by deteriorating or preventing OA occurrence or development. The catabolic effect is mainly to recruit inflammatory cells, inhibit chondrocyte proliferation, accelerate matrix degradation, or induce cell apoptosis. In opposite, the anabolic effect is mainly to reduce the production of catabolic enzymes, promote the proliferation of chondrocytes, inhibit chondrocyte apoptosis, promote the expression of ECM, or inhibit the expression of inflammatory factors. The main pathways involved in OA treatment are NF-κB, Notch, Wnt/β-catenin, TGF-β, Erk, p38 MAPK, JAK2/STAT3, and so on. At present, most researches on biologic agents are in vitro experiments or animal model experiments. There are still many obstacles to overcome for the biologics agents: (1) safety concern is the first to be considered when applying viral vectors to deliver plasmids, ncRNAs, which may bind to multiple targets; and exosomes and proteins, which may result in immunoresponse and disease transmission; (2) efficacy of most of the biologic agents in OA therapy is various and still yet to be verified; (3) heterogeneity of disease may also affect the therapeutic outcomes. With the advancement of molecular biotechnology in future research, translation research should be considered to address the limitations before clinical trials.

Conclusion

We have reviewed a wide spectrum of biologic agents in OA therapy, including DNA, RNA, protein, and exosomes, which provide an insight in finding potential therapeutic targets. Although significant progress has been made in this field, translational research is needed to further address the safety concerns, various efficacies, and heterogenetic of OA.

Statements

Author contributions

JD, ZZ, ZS, and HC did literature retrieval and prepared the draft, JD, JH, and YN made the first revision of the manuscript, HZ and BW finalized the manuscript.

Funding

This project was funded by Natural Science Foundation of Guangdong Province Science and Technology Department (2020A1515010003 and 2019A1515110724), Natural Science Foundation of China (NSFC, 81874000), Medical Research Fund of Guangdong Province (A2020151), “Peaking Plan” for the construction of high-level hospital at Affiliated Hospital of Guangdong Medical University (20501DFY20190168), Discipline construction project of Guangdong Medical University (4SG21002G), and also supported by the Science and Technology Project of Zhanjiang city (2020A01025 and 2019A01029).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.772678/full#supplementary-material

Abbreviations

CircRNA, circular RNA; FGF, fibroblast growth factor; HA–PRP, hyaluronic acid–platelet-rich plasma; IGFBP, insulin-like growth factor–binding proteins; lncRNA, long noncoding RNA; LP-PRP, leukocyte-poor–platelet-rich plasma; LR-PRP, leukocyte-rich–platelet-rich plasma; miRNA, microRNA; OA, osteoarthritis; PRP, platelet-rich plasma; TGF-β, transforming growth factor β.

References

  • 1

    AiD.YuF. (2019). LncRNA DNM3OS Promotes Proliferation and Inhibits Apoptosis through Modulating IGF1 Expression by Sponging MiR-126 in CHON-001 Cells. Diagn. Pathol.14, 106. 10.1186/s13000-019-0877-2

  • 2

    AkbariA.JabbariN.SharifiR.AhmadiM.VahhabiA.SeyedzadehS. J.et al (2020). Free and Hydrogel Encapsulated Exosome-Based Therapies in Regenerative Medicine. Life Sci.249, 117447. 10.1016/j.lfs.2020.117447

  • 3

    ApostuD.LucaciuO.MesterA.Oltean-DanD.BaciutM.BaciutG.et al (2019). Systemic Drugs with Impact on Osteoarthritis. Drug Metab. Rev.51, 498–523. 10.1080/03602532.2019.1687511

  • 4

    BaiJ.ZhangY.ZhengX.HuangM.ChengW.ShanH.et al (2020). LncRNA MM2P-Induced, Exosome-Mediated Transfer of Sox9 from Monocyte-Derived Cells Modulates Primary Chondrocytes. Cell Death Dis11, 763. 10.1038/s41419-020-02945-5

  • 5

    BerenbaumF.BlancoF. J.GuermaziA.MikiK.YamabeT.ViktrupL.et al (2020). Subcutaneous Tanezumab for Osteoarthritis of the Hip or Knee: Efficacy and Safety Results from a 24-week Randomised Phase III Study with a 24-week Follow-Up Period. Ann. Rheum. Dis.79, 800–810. 10.1136/annrheumdis-2019-216296

  • 6

    BerettiF.ZavattiM.CasciaroF.ComitiniG.FranchiF.BarbieriV.et al (2018). Amniotic Fluid Stem Cell Exosomes: Therapeutic Perspective. Biofactors44, 158–167. 10.1002/biof.1407

  • 7

    CaoL.WangY.WangQ.HuangJ. (2018). LncRNA FOXD2-AS1 Regulates Chondrocyte Proliferation in Osteoarthritis by Acting as a Sponge of miR-206 to Modulate CCND1 Expression. Biomed. Pharmacother.106, 1220–1226. 10.1016/j.biopha.2018.07.048

  • 8

    ÇelikE.BayramC.DenkbaşE. B. (2019). Chondrogenesis of Human Mesenchymal Stem Cells by microRNA Loaded Triple Polysaccharide Nanoparticle System. Mater. Sci. Eng. C Mater. Biol. Appl.102, 756–763. 10.1016/j.msec.2019.05.006

  • 9

    ChangY. H.WuK. C.HarnH. J.LinS. Z.DingD. C. (2018). Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy. Cel Transpl.27, 349–363. 10.1177/0963689717723636

  • 10

    CheleschiS.TentiS.MondanelliN.CoralloC.BarbarinoM.GiannottiS.et al (2019). MicroRNA-34a and MicroRNA-181a Mediate Visfatin-Induced Apoptosis and Oxidative Stress via NF-Κb Pathway in Human Osteoarthritic Chondrocytes. Cells8. 10.3390/cells8080874

  • 11

    ChenC.YinP.HuS.SunX.LiB. (2020). Circular RNA-9119 Protects IL-1β-treated Chondrocytes from Apoptosis in an Osteoarthritis Cell Model by Intercepting the microRNA-26a/PTEN axis. Life Sci.256, 117924. 10.1016/j.lfs.2020.117924

  • 12

    ChenG.LiuT.YuB.WangB.PengQ. (2020). CircRNA-UBE2G1 Regulates LPS-Induced Osteoarthritis through miR-373/HIF-1a axis. Cell Cycle19, 1696–1705. 10.1080/15384101.2020.1772545

  • 13

    ChenK.ZhuH.ZhengM. Q.DongQ. R. (2019). LncRNA MEG3 Inhibits the Degradation of the Extracellular Matrix of Chondrocytes in Osteoarthritis via Targeting miR-93/TGFBR2 Axis. Cartilage, 1947603519855759.

  • 14

    ChuP.WangQ.WangZ.GaoC. (2019). Long Non-coding RNA Highly Up-Regulated in Liver Cancer Protects Tumor Necrosis Factor-Alpha-Induced Inflammatory Injury by Down-Regulation of microRNA-101 in ATDC5 Cells. Int. Immunopharmacol72, 148–158. 10.1016/j.intimp.2019.04.004

  • 15

    CongL.ZhuY.TuG. (2017). A Bioinformatic Analysis of microRNAs Role in Osteoarthritis. Osteoarthritis Cartilage25, 1362–1371. 10.1016/j.joca.2017.03.012

  • 16

    D'AdamoS.CetrulloS.GuidottiS.BorzìR. M.FlamigniF. (2017). Hydroxytyrosol Modulates the Levels of microRNA-9 and its Target Sirtuin-1 Thereby Counteracting Oxidative Stress-Induced Chondrocyte Death. Osteoarthritis Cartilage25, 600–610. 10.1016/j.joca.2016.11.014

  • 17

    DakinP.KivitzA. J.GimbelJ. S.SkrepnikN.DiMartinoS. J.EmeremniC. A.et al (2020). Efficacy and Safety of Fasinumab in Patients with Chronic Low Back Pain: a Phase II/III Randomised Clinical Trial. Ann. Rheum. Dis.80, 509–517. 10.1136/annrheumdis-2020-217259

  • 18

    DenkF.BennettD. L.McMahonS. B. (2017). Nerve Growth Factor and Pain Mechanisms. Annu. Rev. Neurosci.40, 307–325. 10.1146/annurev-neuro-072116-031121

  • 19

    DuanL.LiangY.XuX.WangJ.LiX.SunD.et al (2020). Noncoding RNAs in Subchondral Bone Osteoclast Function and Their Therapeutic Potential for Osteoarthritis. Arthritis Res. Ther.22, 279. 10.1186/s13075-020-02374-x

  • 20

    DurandA. L.DufourA.Aubert-FoucherE.Oger-DesfeuxC.PasdeloupM.LustigS.et al (2020). The Lysine Specific Demethylase-1 Negatively Regulates the COL9A1 Gene in Human Articular Chondrocytes. Int. J. Mol. Sci.21. 10.3390/ijms21176322

  • 21

    EcksteinF.KrainesJ. L.AydemirA.WirthW.MaschekS.HochbergM. C. (2020). Intra-articular Sprifermin Reduces Cartilage Loss in Addition to Increasing Cartilage Gain Independent of Location in the Femorotibial Joint: post-hoc Analysis of a Randomised, Placebo-Controlled Phase II Clinical Trial. Ann. Rheum. Dis.79, 525–528. 10.1136/annrheumdis-2019-216453

  • 22

    EvansC. H.GhivizzaniS. C.RobbinsP. D. (2018). Gene Delivery to Joints by Intra-articular Injection. Hum. Gene Ther.29, 2–14. 10.1089/hum.2017.181

  • 23

    FranciscoV.PérezT.PinoJ.LópezV.FrancoE.AlonsoA.et al (2018). Biomechanics, Obesity, and Osteoarthritis. The Role of Adipokines: When the Levee Breaks. J. Orthop. Res.36, 594–604. 10.1002/jor.23788

  • 24

    FuQ.ZhuJ.WangB.WuJ.LiH.HanY.et al (2021). LINC02288 Promotes Chondrocyte Apoptosis and Inflammation through miR-374a-3p Targeting RTN3. J. Gene Med.23, e3314. 10.1002/jgm.3314

  • 25

    GademanM. G.HofstedeS. N.Vliet VlielandT. P.NelissenR. G.Marang-van de MheenP. J. (2016). Indication Criteria for Total Hip or Knee Arthroplasty in Osteoarthritis: a State-Of-The-Science Overview. BMC Musculoskelet. Disord.17, 463. 10.1186/s12891-016-1325-z

  • 26

    GaoF.PengC.ZhengC.ZhangS.WuM. (2019). miRNA-101 Promotes Chondrogenic Differentiation in Rat Bone Marrow Mesenchymal Stem Cells. Exp. Ther. Med.17, 175–180. 10.3892/etm.2018.6959

  • 27

    GaoK.ZhuW.LiH.MaD.LiuW.YuW.et al (2020). Association between Cytokines and Exosomes in Synovial Fluid of Individuals with Knee Osteoarthritis. Mod. Rheumatol.30, 758–764. 10.1080/14397595.2019.1651445

  • 28

    GengR.XuY.HuW.ZhaoH. (2018). The Association between MMP-1 Gene Rs1799750 Polymorphism and Knee Osteoarthritis Risk. Biosci. Rep.38. 10.1042/BSR20181257

  • 29

    GentileP.CalabreseC.De AngelisB.DionisiL.PizzicannellaJ.KothariA.et al (2020). Impact of the Different Preparation Methods to Obtain Autologous Non-activated Platelet-Riched Plasma (A-PRP) and Activated Platelet-Riched Plasma (AA-PRP) in Plastic Surgery: Wound Healing and Hair Regrowth Evaluation. Int. J. Mol. Sci.21. 10.3390/ijms21020431

  • 30

    Ghafouri-FardS.AbakA.Tavakkoli AvvalS.RahmaniS.ShooreiH.TaheriM.et al (2021). Contribution of miRNAs and lncRNAs in Osteogenesis and Related Disorders. Biomed. Pharmacother.142, 111942. 10.1016/j.biopha.2021.111942

  • 31

    GoldringS. R.GoldringM. B. (2016). Changes in the Osteochondral Unit during Osteoarthritis: Structure, Function and Cartilage-Bone Crosstalk. Nat. Rev. Rheumatol.12, 632–644. 10.1038/nrrheum.2016.148

  • 32

    GrässelS.MuschterD. (2020). Recent Advances in the Treatment of Osteoarthritis. F1000Res9. 10.12688/f1000research.22115.1

  • 33

    GuillénM. I.CompañA.AlcarazM. J. (2021). Evaluation of Extracellular Vesicles from Adipose Tissue-Derived Mesenchymal Stem Cells in Primary Human Chondrocytes from Patients with Osteoarthritis. Methods Mol. Biol.2269, 221–231. 10.1007/978-1-0716-1225-5_15

  • 34

    HanW.LiuJ. (2018). LncRNA-p21 Inhibited the Proliferation of Osteosarcoma Cells via the miR-130b/PTEN/AKT Signaling Pathway. Biomed. Pharmacother.97, 911–918. 10.1016/j.biopha.2017.11.014

  • 35

    HeB.JiangD. (2020). HOTAIR-induced Apoptosis Is Mediated by Sponging miR-130a-3p to Repress Chondrocyte Autophagy in Knee Osteoarthritis. Cell Biol Int44, 524–535. 10.1002/cbin.11253

  • 36

    HeC. P.JiangX. C.ChenC.ZhangH. B.CaoW. D.WuQ.et al (2021). The Function of lncRNAs in the Pathogenesis of Osteoarthritis. Bone Jt. Res10, 122–133. 10.1302/2046-3758.102.BJR-2020-0228.R1

  • 37

    HeJ.CaoW.AzeemI.ShaoZ. (2020). Epigenetics of Osteoarthritis: Histones and TGF-Β1. Clin. Chim. Acta510, 593–598. 10.1016/j.cca.2020.08.011

  • 38

    HeJ.SuX.XieW. (2020). MiR-582-3p Alleviates Osteoarthritis Progression by Targeting YAP1. Mol. Immunol.128, 258–267. 10.1016/j.molimm.2020.10.022

  • 39

    HeX.GaoK.LuS.WuR. (2021). LncRNA HOTTIP Leads to Osteoarthritis Progression via Regulating miR-663a/Fyn-Related Kinase axis. BMC Musculoskelet. Disord.22, 67. 10.1186/s12891-020-03861-7

  • 40

    HeY.YaoW.ZhangM.ZhangY.ZhangD.JiangZ.et al (2018). Changes in Osteogenic Gene Expression in Hypertrophic Chondrocytes Induced by SIN-1. Exp. Ther. Med.16, 609–618. 10.3892/etm.2018.6261

  • 41

    HermannW.LambovaS.Muller-LadnerU. (2018). Current Treatment Options for Osteoarthritis. Curr. Rheumatol. Rev.14, 108–116. 10.2174/1573397113666170829155149

  • 42

    HuG.ZhaoX.WangC.GengY.ZhaoJ.XuJ.et al (2017). MicroRNA-145 Attenuates TNF-α-Driven Cartilage Matrix Degradation in Osteoarthritis via Direct Suppression of MKK4. Cel Death Dis8, e3140. 10.1038/cddis.2017.522

  • 43

    HuJ.WangZ.ShanY.PanY.MaJ.JiaL. (2018). Long Non-coding RNA HOTAIR Promotes Osteoarthritis Progression via miR-17-5p/FUT2/β-Catenin axis. Cel Death Dis9, 711. 10.1038/s41419-018-0746-z

  • 44

    HuY.LiS.ZouY. (2019). Knockdown of LncRNA H19 Relieves LPS-Induced Damage by Modulating miR-130a in Osteoarthritis. Yonsei Med. J.60, 381–388. 10.3349/ymj.2019.60.4.381

  • 45

    HuangB.YuH.LiY.ZhangW.LiuX. (2019). Upregulation of Long Noncoding TNFSF10 Contributes to Osteoarthritis Progression through the miR-376-3p/FGFR1 axis. J. Cel Biochem120, 19610–19620. 10.1002/jcb.29267

  • 46

    HuangJ.LiuL.YangJ.DingJ.XuX. (2019). lncRNA DILC Is Downregulated in Osteoarthritis and Regulates IL-6 Expression in Chondrocytes. J. Cel Biochem120, 16019–16024. 10.1002/jcb.28880

  • 47

    HuangJ.ZhaoL.FanY.LiaoL.MaP. X.XiaoG.et al (2019). The microRNAs miR-204 and miR-211 Maintain Joint Homeostasis and Protect against Osteoarthritis Progression. Nat. Commun.10, 2876. 10.1038/s41467-019-10753-5

  • 48

    HuangT.WangJ.ZhouY.ZhaoY.HangD.CaoY. (2019). LncRNA CASC2 Is Up-Regulated in Osteoarthritis and Participates in the Regulation of IL-17 Expression and Chondrocyte Proliferation and Apoptosis. Biosci. Rep.39. 10.1042/BSR20182454

  • 49

    HunterD. J.MarchL.ChewM. (2020). Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet396, 1711–1712. 10.1016/S0140-6736(20)32230-3

  • 50

    IezakiT.OzakiK.FukasawaK.InoueM.KitajimaS.MunetaT.et al (2016). ATF3 Deficiency in Chondrocytes Alleviates Osteoarthritis Development. J. Pathol.239, 426–437. 10.1002/path.4739

  • 51

    JiM. L.JiangH.WuF.GengR.YaL. K.LinY. C.et al (2020). Precise Targeting of miR-141/200c Cluster in Chondrocytes Attenuates Osteoarthritis Development. Ann. Rheum. Dis.80 (3), 356–366. 10.1136/annrheumdis-2020-218469

  • 52

    JiQ.QiD.XuX.XuY.GoodmanS. B.KangL.et al (2018). Cryptotanshinone Protects Cartilage against Developing Osteoarthritis through the miR-106a-5p/GLIS3 Axis. Mol. Ther. Nucleic Acids11, 170–179. 10.1016/j.omtn.2018.02.001

  • 53

    JiQ.QiaoX.LiuY.WangD.YanJ. (2020). Silencing of Long-chain N-on-coding RNA GAS5 in O-steoarthritic C-hondrocytes I-s M-ediated by T-argeting the miR-34a/Bcl-2 axis. Mol. Med. Rep.21, 1310–1319. 10.3892/mmr.2019.10900

  • 54

    JiangL.LinJ.ZhaoS.WuJ.JinY.YuL.et al (2021). ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies. Front. Mol. Biosci.8, 703110. 10.3389/fmolb.2021.703110

  • 55

    JiangM.LiuJ.LuoT.ChenQ.LuM.MengD. (2019). LncRNA PACER Is Down-Regulated in Osteoarthritis and Regulates Chondrocyte Apoptosis and lncRNA HOTAIR Expression. Biosci. Rep.39. 10.1042/BSR20190404

  • 56

    KangX.QianZ.LiuJ.FengD.LiH.ZhangZ.et al (2020). Neuropeptide Y Acts Directly on Cartilage Homeostasis and Exacerbates Progression of Osteoarthritis through NPY2R. J. Bone Miner Res.35, 1375–1384. 10.1002/jbmr.3991

  • 57

    KaniaK.ColellaF.RiemenA. H. K.WangH.HowardK. A.AignerT.et al (2020). Regulation of Gdf5 Expression in Joint Remodelling, Repair and Osteoarthritis. Sci. Rep.10, 157. 10.1038/s41598-019-57011-8

  • 58

    KimY. G.ChoiJ.KimK. (2020). Mesenchymal Stem Cell-Derived Exosomes for Effective Cartilage Tissue Repair and Treatment of Osteoarthritis. Biotechnol. J.15, e2000082. 10.1002/biot.202000082

  • 59

    KomoriT. (2016). Glucocorticoid Signaling and Bone Biology. Horm. Metab. Res.48, 755–763. 10.1055/s-0042-110571

  • 60

    LeiJ.FuY.ZhuangY.ZhangK.LuD. (2019). LncRNA SNHG1 Alleviates IL-1β-induced Osteoarthritis by Inhibiting miR-16-5p-Mediated P38 MAPK and NF-Κb Signaling Pathways. Biosci. Rep.39. 10.1042/BSR20191523

  • 61

    LiB. F.ZhangY.XiaoJ.WangF.LiM.GuoX. Z.et al (2017). Hsa_circ_0045714 Regulates Chondrocyte Proliferation, Apoptosis and Extracellular Matrix Synthesis by Promoting the Expression of miR-193b Target Gene IGF1R. Hum. Cel30, 311–318. 10.1007/s13577-017-0177-7

  • 62

    LiC.LuoJ.XuX.ZhouZ.YingS.LiaoX.et al (2020). Single Cell Sequencing Revealed the Underlying Pathogenesis of the Development of Osteoarthritis. Gene757, 144939. 10.1016/j.gene.2020.144939

  • 63

    LiC.PanS.SongY.LiY.QuJ. (2019). Silence of lncRNA MIAT Protects ATDC5 Cells against Lipopolysaccharides challenge via Up-Regulating miR-132. Artif. Cell Nanomed Biotechnol47, 2521–2527. 10.1080/21691401.2019.1626410

  • 64

    LiH.YangH. H.SunZ. G.TangH. B.MinJ. K. (2019). Whole-transcriptome Sequencing of Knee Joint Cartilage from Osteoarthritis Patients. Bone Jt. Res8, 290–303. 10.1302/2046-3758.87.BJR-2018-0297.R1

  • 65

    LiL.LvG.WangB.KuangL. (2018). The Role of lncRNA XIST/miR-211 axis in Modulating the Proliferation and Apoptosis of Osteoarthritis Chondrocytes through CXCR4 and MAPK Signaling. Biochem. Biophys. Res. Commun.503, 2555–2562. 10.1016/j.bbrc.2018.07.015

  • 66

    LiL.ZhangL.ZhangY.JiangD.XuW.ZhaoH.et al (2019). Inhibition of Long Non-coding RNA CTD-2574D22.4 Alleviates LPS-Induced Apoptosis and Inflammatory Injury of Chondrocytes. Curr. Pharm. Des.25, 2969–2974. 10.2174/1381612825666190801141801

  • 67

    LiQ.ZhangZ.GuoS.TangG.LuW.QiX. (2019). LncRNA ANCR Is Positively Correlated with Transforming Growth Factor-Β1 in Patients with Osteoarthritis. J. Cel Biochem120, 14226–14232. 10.1002/jcb.28881

  • 68

    LiX.HuangT. L.ZhangG. D.JiangJ. T.GuoP. Y. (2019). LncRNA ANRIL Impacts the Progress of Osteoarthritis via Regulating Proliferation and Apoptosis of Osteoarthritis Synoviocytes. Eur. Rev. Med. Pharmacol. Sci.23, 9729–9737. 10.26355/eurrev_201911_19535

  • 69

    LiX.RenW.XiaoZ. Y.WuL. F.WangH.GuoP. Y. (2018). GACAT3 Promoted Proliferation of Osteoarthritis Synoviocytes by IL-6/STAT3 Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci.22, 5114–5120. 10.26355/eurrev_201808_15705

  • 70

    LiX.YuM.ChenL.SunT.WangH.ZhaoL.et al (2019). LncRNA PMS2L2 Protects ATDC5 Chondrocytes against Lipopolysaccharide-Induced Inflammatory Injury by Sponging miR-203. Life Sci.217, 283–292. 10.1016/j.lfs.2018.12.020

  • 71

    LiX. F.WangZ. Q.LiL. Y.ZhaoG. Q.YuS. N. (2018). Downregulation of the Long Noncoding RNA MBNL1-AS1 Protects Sevoflurane-Pretreated Mice against Ischemia-Reperfusion Injury by Targeting KCNMA1. Exp. Mol. Med.50, 115–116. 10.1038/s12276-018-0133-y

  • 72

    LiY.LiS.LuoY.LiuY.YuN. (2017). LncRNA PVT1 Regulates Chondrocyte Apoptosis in Osteoarthritis by Acting as a Sponge for miR-488-3p. DNA Cel Biol36, 571–580. 10.1089/dna.2017.3678

  • 73

    LiY.LiZ.LiC.ZengY.LiuY. (2019). Long Noncoding RNA TM1P3 Is Involved in Osteoarthritis by Mediating Chondrocyte Extracellular Matrix Degradation. J. Cel Biochem120, 12702–12712. 10.1002/jcb.28539

  • 74

    LiY. F.LiS. H.LiuY.LuoY. T. (2017). Long Noncoding Rna Cir Promotes Chondrocyte Extracellular Matrix Degradation in Osteoarthritis by Acting as a Sponge for Mir-27b. Cell Physiol Biochem43, 602–610. 10.1159/000480532

  • 75

    LiZ.ChengJ.LiuJ. (2020). Baicalin Protects Human OA Chondrocytes against IL-1β-Induced Apoptosis and ECM Degradation by Activating Autophagy via MiR-766-3p/AIFM1 Axis. Drug Des. Devel Ther.14, 2645–2655. 10.2147/DDDT.S255823

  • 76

    LiZ.YuanB.PeiZ.ZhangK.DingZ.ZhuS.et al (2019). Circ_0136474 and MMP-13 Suppressed Cell Proliferation by Competitive Binding to miR-127-5p in Osteoarthritis. J. Cel Mol Med23, 6554–6564. Circ_0136474. 10.1111/jcmm.14400

  • 77

    LiaoH. X.ZhangZ. H.ChenH. L.HuangY. M.LiuZ. L.HuangJ. (2021). CircHYBID Regulates Hyaluronan Metabolism in Chondrocytes via Hsa-miR-29b-3p/TGF-Β1 axis. Mol. Med.27, 56. 10.1186/s10020-021-00319-x

  • 78

    LinJ.WuG.ZhaoZ.HuangY.ChenJ.FuC.et al (2018). Bioinformatics Analysis to Identify Key Genes and Pathways Influencing Synovial Inflammation in Osteoarthritis. Mol. Med. Rep.18, 5594–5602. 10.3892/mmr.2018.9575

  • 79

    LinS. S.YuanL. J.NiuC. C.TuY. K.YangC. Y.UengS. W. N. (2019). Hyperbaric Oxygen Inhibits the HMGB1/RAGE Signaling Pathway by Upregulating Mir-107 Expression in Human Osteoarthritic Chondrocytes. Osteoarthritis Cartilage27, 1372–1381. 10.1016/j.joca.2019.05.011

  • 80

    LinT.WuN.WangL.ZhangR.PanR.ChenY-F. (2021). Inhibition of Chondrocyte Apoptosis in a Rat Model of Osteoarthritis by Exosomes Derived from miR-140-5p-Overexpressing Human Dental Pulp Stem Cells. Int. J. Mol. Med.47. 10.3892/ijmm.2020.4840

  • 81

    LiuF.LiuX.YangY.SunZ.DengS.JiangZ.et al (2020). NEAT1/miR-193a-3p/SOX5 axis Regulates Cartilage Matrix Degradation in Human Osteoarthritis. Cel Biol Int44, 947–957. 10.1002/cbin.11291

  • 82

    LiuG.WangY.ZhangM.ZhangQ. (2019). Long Non-coding RNA THRIL Promotes LPS-Induced Inflammatory Injury by Down-Regulating microRNA-125b in ATDC5 Cells. Int. Immunopharmacol66, 354–361. 10.1016/j.intimp.2018.11.038

  • 83

    LiuJ.YuQ.YeY.YanY.ChenX. (2018). Abnormal Expression of miR-4784 in Chondrocytes of Osteoarthritis and Associations with Chondrocyte Hyperplasia. Exp. Ther. Med.16, 4690–4694. 10.3892/etm.2018.6739

  • 84

    LiuQ.HuX.ZhangX.DaiL.DuanX.ZhouC.et al (2016). The TMSB4 Pseudogene LncRNA Functions as a Competing Endogenous RNA to Promote Cartilage Degradation in Human Osteoarthritis. Mol. Ther.24, 1726–1733. 10.1038/mt.2016.151

  • 85

    LiuX.LiuL.ZhangH.ShaoY.ChenZ.FengX.et al (2019). MiR-146b Accelerates Osteoarthritis Progression by Targeting Alpha-2-Macroglobulin. Aging (Albany NY)11, 6014–6028. 10.18632/aging.102160

  • 86

    LiuX.WangL.MaC.WangG.ZhangY.SunS. (2019). Exosomes Derived from Platelet-Rich Plasma Present a Novel Potential in Alleviating Knee Osteoarthritis by Promoting Proliferation and Inhibiting Apoptosis of Chondrocyte via Wnt/β-Catenin Signaling Pathway. J. Orthop. Surg. Res.14, 470. 10.1186/s13018-019-1529-7

  • 87

    LiuY.LiQ.GaoZ.LeiF.GaoX. (2021). Circ-SPG11 Knockdown Hampers IL-1β-induced Osteoarthritis Progression via Targeting miR-337-3p/ADAMTS5. J. Orthop. Surg. Res.16, 392. 10.1186/s13018-021-02526-y

  • 88

    LuC.LiZ.HuS.CaiY.PengK. (2019). LncRNA PART-1 Targets TGFBR2/Smad3 to Regulate Cell Viability and Apoptosis of Chondrocytes via Acting as miR-590-3p Sponge in Osteoarthritis. J. Cel Mol Med23, 8196–8205. 10.1111/jcmm.14690

  • 89

    LuC.ShuJ.HanY.RenX. Y.XuK.FanH.et al (2019). The Polymorphism of SMAD3 Rs1065080 Is Associated with Increased Risk for Knee Osteoarthritis. Mol. Biol. Rep.46, 4501–4505. 10.1007/s11033-019-04905-5

  • 90

    LuJ.JiM. L.ZhangX. J.ShiP. L.WuH.WangC.et al (2017). MicroRNA-218-5p as a Potential Target for the Treatment of Human Osteoarthritis. Mol. Ther.25, 2676–2688. 10.1016/j.ymthe.2017.08.009

  • 91

    LuX.LiY.ChenH.PanY.LinR.ChenS. (2021). miR-335-5P Contributes to Human Osteoarthritis by Targeting HBP1. Exp. Ther. Med.21, 109. 10.3892/etm.2020.9541

  • 92

    LvZ. T.LiangS.HuangX. J.ChengP.ZhuW. T.ChenA. M. (2017). Association between ADAM12 Single-Nucleotide Polymorphisms and Knee Osteoarthritis: A Meta-Analysis. Biomed. Res. Int.2017, 5398181. 10.1155/2017/5398181

  • 93

    LyuH.XiaoY.GuoQ.HuangY.LuoX. (2020). The Role of Bone-Derived Exosomes in Regulating Skeletal Metabolism and Extraosseous Diseases. Front Cel Dev Biol8, 89. 10.3389/fcell.2020.00089

  • 94

    MaH. R.MuW. B.ZhangK. Y.ZhouH. K.JiangR. D.CaoL. (2020). CircVCAN Regulates the Proliferation and Apoptosis of Osteoarthritis Chondrocyte through NF-Κb Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci.24, 6517–6525. 10.26355/eurrev_202006_21635

  • 95

    MalemudC. J. (2018). MicroRNAs and Osteoarthritis. Cells7. 10.3390/cells7080092

  • 96

    MinchinS.LodgeJ. (2019). Understanding Biochemistry: Structure and Function of Nucleic Acids. Essays Biochem.63, 433–456. 10.1042/EBC20180038

  • 97

    Miranda-DuarteA. (2018). DNA Methylation in Osteoarthritis: Current Status and Therapeutic Implications. Open Rheumatol. J.12, 37–49. 10.2174/1874312901812010037

  • 98

    MoussaM.LajeunesseD.HilalG.El AtatO.HaykalG.SerhalR.et al (2017). Platelet Riched Plasma (PRP) Induces Chondroprotection via Increasing Autophagy, Anti-inflammatory Markers, and Decreasing Apoptosis in Human Osteoarthritic Cartilage. Exp. Cel Res352, 146–156. 10.1016/j.yexcr.2017.02.012

  • 99

    MurrayD. W.ParkinsonR. W. (2018). Usage of Unicompartmental Knee Arthroplasty. Bone Jt. J100-b, 432–435. 10.1302/0301-620X.100B4.BJJ-2017-0716.R1

  • 100

    NiJ. L.DangX. Q.ShiZ. B. (2020). CircPSM3 Inhibits the Proliferation and Differentiation of OA Chondrocytes by Targeting miRNA-296-5p. Eur. Rev. Med. Pharmacol. Sci.24, 3467–3475. 10.26355/eurrev_202004_20805

  • 101

    NiZ.ZhouS.LiS.KuangL.ChenH.LuoX.et al (2020). Exosomes: Roles and Therapeutic Potential in Osteoarthritis. Bone Res.8, 25. 10.1038/s41413-020-0100-9

  • 102

    ParkS.LeeM.ChunC. H.JinE. J. (2019). The lncRNA, Nespas, Is Associated with Osteoarthritis Progression and Serves as a Potential New Prognostic Biomarker. Cartilage10, 148–156. 10.1177/1947603517725566

  • 103

    PegtelD. M.GouldS. J. (2019). Exosomes. Annu. Rev. Biochem.88, 487–514. 10.1146/annurev-biochem-013118-111902

  • 104

    Pérez-GarcíaS.CarriónM.Gutiérrez-CañasI.Villanueva-RomeroR.CastroD.MartínezC.et al (2019). Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin. Cells9, 40. 10.3390/cells9010040

  • 105

    QiK.LinR.XueC.LiuT.WangY.ZhangY.et al (2019). Long Non-coding RNA (LncRNA) CAIF Is Downregulated in Osteoarthritis and Inhibits LPS-Induced Interleukin 6 (IL-6) Upregulation by Downregulation of MiR-1246. Med. Sci. Monit.25, 8019–8024. 10.12659/MSM.917135

  • 106

    QiuM.LiuD.FuQ. (2021). MiR-129-5p Shuttled by Human Synovial Mesenchymal Stem Cell-Derived Exosomes Relieves IL-1β Induced Osteoarthritis via Targeting HMGB1. Life Sci.269, 118987. 10.1016/j.lfs.2020.118987

  • 107

    RajanP. V.NgM. K.KlikaA.KamathA. F.MuschlerG. F.HigueraC. A.et al (2020). The Cost-Effectiveness of Platelet-Rich Plasma Injections for Knee Osteoarthritis: A Markov Decision Analysis. J. Bone Jt. Surg Am102, e104. 10.2106/JBJS.19.01446

  • 108

    RheeJ.ParkS. H.KimS. K.KimJ. H.HaC. W.ChunC. H.et al (2017). Inhibition of BATF/JUN Transcriptional Activity Protects against Osteoarthritic Cartilage Destruction. Ann. Rheum. Dis.76, 427–434. 10.1136/annrheumdis-2015-208953

  • 109

    SacksD.SacksD.BaxterB.CampbellB. C. V.CarpenterJ. S.CognardC.et al (2018). Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. AJNR Am. J. Neuroradiol39, E61–E632. 10.3174/ajnr.A5638

  • 110

    SekarD. (2021). Implications of microRNA 21 and its Involvement in the Treatment of Different Type of Arthritis. Mol. Cel Biochem476, 941–947. 10.1007/s11010-020-03960-y

  • 111

    ShangH.HaoY.HuW.HuX.JinQ. (2019). Association between ADIPOQ Gene Variants and Knee Osteoarthritis in a Chinese Population. Biosci. Rep.39. 10.1042/BSR20182104

  • 112

    ShenS.WuY.ChenJ.XieZ.HuangK.WangG.et al (2019). CircSERPINE2 Protects against Osteoarthritis by Targeting miR-1271 and ETS-Related Gene. Ann. Rheum. Dis.78, 826–836. 10.1136/annrheumdis-2018-214786

  • 113

    SiH. B.ZengY.LiuS. Y.ZhouZ. K.ChenY. N.ChengJ. Q.et al (2017). Intra-articular Injection of microRNA-140 (miRNA-140) Alleviates Osteoarthritis (OA) Progression by Modulating Extracellular Matrix (ECM) Homeostasis in Rats. Osteoarthritis Cartilage25, 1698–1707. 10.1016/j.joca.2017.06.002

  • 114

    SongY.HaoD.JiangH.HuangM.DuQ.LinY.et al (2021). Nrf2 Regulates CHI3L1 to Suppress Inflammation and Improve Post-Traumatic Osteoarthritis. JirVol. 14, 4079–4088. 10.2147/jir.s310831

  • 115

    SunK.GuoJ.YaoX.GuoZ.GuoF. (2021). Growth Differentiation Factor 5 in Cartilage and Osteoarthritis: A Possible Therapeutic Candidate. Cell Prolif54, e12998. 10.1111/cpr.12998

  • 116

    SzwedowskiD.SzczepanekJ.PaczesnyŁ.ZabrzyńskiJ.GagatM.MobasheriA.et al (2021). The Effect of Platelet-Rich Plasma on the Intra-articular Microenvironment in Knee Osteoarthritis. Int. J. Mol. Sci.22. 10.3390/ijms22115492

  • 117

    TamC.WongJ. H.TsuiS. K. W.ZuoT.ChanT. F.NgT. B. (2019). LncRNAs with miRNAs in Regulation of Gastric, Liver, and Colorectal Cancers: Updates in Recent Years. Appl. Microbiol. Biotechnol.103, 4649–4677. 10.1007/s00253-019-09837-5

  • 118

    TanakaN.TsunoH.OhashiS.IwasawaM.FurukawaH.KatoT.et al (2021). The Attenuation of Insulin-like Growth Factor Signaling May Be Responsible for Relative Reduction in Matrix Synthesis in Degenerated Areas of Osteoarthritic Cartilage. BMC Musculoskelet. Disord.22, 231. 10.1186/s12891-021-04096-w

  • 119

    TangL. P.DingJ. B.LiuZ. H.ZhouG. J. (2018). LncRNA TUG1 Promotes Osteoarthritis-Induced Degradation of Chondrocyte Extracellular Matrix via miR-195/MMP-13 axis. Eur. Rev. Med. Pharmacol. Sci.22, 8574–8581. 10.26355/eurrev_201812_16620

  • 120

    TaoK.Rey-RicoA.FrischJ.VenkatesanJ. K.SchmittG.MadryH.et al (2016). rAAV-Mediated Combined Gene Transfer and Overexpression of TGF-β and SOX9 Remodels Human Osteoarthritic Articular Cartilage. J. Orthop. Res.34, 2181–2190. 10.1002/jor.23228

  • 121

    Tofiño-VianM.GuillénM. I.Pérez Del CazM. D.SilvestreA.AlcarazM. J. (2018). Microvesicles from Human Adipose Tissue-Derived Mesenchymal Stem Cells as a New Protective Strategy in Osteoarthritic Chondrocytes. Cel Physiol Biochem47, 11–25. 10.1159/000489739

  • 122

    TohW. S.LaiR. C.HuiJ. H. P.LimS. K. (2017). MSC Exosome as a Cell-free MSC Therapy for Cartilage Regeneration: Implications for Osteoarthritis Treatment. Semin. Cel Dev Biol67, 56–64. 10.1016/j.semcdb.2016.11.008

  • 123

    TongW.ZengY.ChowD. H. K.YeungW.XuJ.DengY.et al (2019). Wnt16 Attenuates Osteoarthritis Progression through a PCP/JNK-mTORC1-PTHrP cascade. Ann. Rheum. Dis.78, 551–561. 10.1136/annrheumdis-2018-214200

  • 124

    TuJ. F.YangJ. W.ShiG. X.YuZ. S.LiJ. L.LinL. L.et al (2021). Efficacy of Intensive Acupuncture versus Sham Acupuncture in Knee Osteoarthritis: A Randomized Controlled Trial. Arthritis Rheumatol.73, 448–458. 10.1002/art.41584

  • 125

    van der WoudeJ. A. D.WiegantK.van HeerwaardenR. J.SpruijtS.van RoermundP. M.CustersR. J. H.et al (2017). Knee Joint Distraction Compared with High Tibial Osteotomy: a Randomized Controlled Trial. Knee Surg. Sports Traumatol. Arthrosc.25, 876–886. 10.1007/s00167-016-4131-0

  • 126

    WangH.ZhangH.SunQ.YangJ.ZengC.DingC.et al (2019). Chondrocyte mTORC1 Activation Stimulates miR-483-5p via HDAC4 in Osteoarthritis Progression. J. Cel Physiol234, 2730–2740. 10.1002/jcp.27088

  • 127

    WangH.ZhangX.WuW.ZhangM.SamN. B.NiuL. (2018). Association between the Aspartic Acid D-Repeat Polymorphisms and Osteoarthritis Susceptibility: An Updated Systematic Review and Meta-Analyses. Medicine (Baltimore)97, e13163. 10.1097/MD.0000000000013163

  • 128

    WangJ.ChenL.JinS.LinJ.ZhengH.ZhangH.et al (2017). Altered Expression of microRNA-98 in IL-1β-induced Cartilage Degradation and its Role in Chondrocyte Apoptosis. Mol. Med. Rep.16, 3208–3216. 10.3892/mmr.2017.7028

  • 129

    WangP.DongR.WangB.LouZ.YingJ.XiaC.et al (2019). Genome-wide microRNA Screening Reveals miR-582-5p as a Mesenchymal Stem Cell-specific microRNA in Subchondral Bone of the Human Knee Joint. J. Cel Physiol234, 21877–21888. 10.1002/jcp.28751

  • 130

    WangW.HanX.ZhaoT.ZhangX.QuP.ZhaoH. (2020). AGT, Targeted by miR-149-5p, Promotes IL-6-induced Inflammatory Responses of Chondrocytes in Osteoarthritis via Activating JAK2/STAT3 Pathway. Clin. Exp. Rheumatol.38, 1088–1095.

  • 131

    WangW. T.HuangZ. P.SuiS.LiuJ. H.YuD. M.WangW. B. (2020). microRNA-1236 Promotes Chondrocyte Apoptosis in Osteoarthritis via Direct Suppression of PIK3R3. Life Sci.253, 117694. 10.1016/j.lfs.2020.117694

  • 132

    WangX.YuY.HuangY.ZhuM.ChenR.LiaoZ.et al (2020). Identification of Potential Diagnostic Gene Biomarkers in Patients with Osteoarthritis. Sci. Rep.10, 13591. 10.1038/s41598-020-70596-9

  • 133

    WangX. B.ZhaoF-C.YiL-H.TangJ-L.ZhuZ-Y.PangY.et al (2019). MicroRNA-21-5p as a Novel Therapeutic Target for Osteoarthritis. Rheumatology58, 1485–1497. 10.1093/rheumatology/kez102

  • 134

    WangY.CaoL.WangQ.HuangJ.XuS. (2019). LncRNA FOXD2-AS1 Induces Chondrocyte Proliferation through Sponging miR-27a-3p in Osteoarthritis. Artif. Cell Nanomed Biotechnol47, 1241–1247. 10.1080/21691401.2019.1596940

  • 135

    WangY.WuC.YangY.RenZ.LammiM. J.GuoX. (2019). Preliminary Exploration of Hsa_circ_0032131 Levels in Peripheral Blood as a Potential Diagnostic Biomarker of Osteoarthritis. Genet. Test. Mol. Biomarkers23, 717–721. 10.1089/gtmb.2019.0036

  • 136

    WangY.WuC.ZhangY.YangY.RenZ.LammiM. J.et al (2020). Screening for Differentially Expressed circRNA between Kashin-Beck Disease and Osteoarthritis Patients Based on circRNA Chips. Clin. Chim. Acta501, 92–101. 10.1016/j.cca.2019.10.026

  • 137

    WangY.YuD.LiuZ.ZhouF.DaiJ.WuB.et al (2017). Exosomes from Embryonic Mesenchymal Stem Cells Alleviate Osteoarthritis through Balancing Synthesis and Degradation of Cartilage Extracellular Matrix. Stem Cel Res Ther8, 189. 10.1186/s13287-017-0632-0

  • 138

    Watson LevingsR. S.BroomeT. A.SmithA. D.RiceB. L.GibbsE. P.MyaraD. A.et al (2018). Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model. Hum. Gene Ther. Clin. Dev.29, 90–100. 10.1089/humc.2017.142

  • 139

    WeiW.HeS.WangZ.DongJ.XiangD.LiY.et al (2019). LINC01534 Promotes the Aberrant Metabolic Dysfunction and Inflammation in IL-1β-Simulated Osteoarthritic Chondrocytes by Targeting miR-140-5p. Cartilage, 1947603519888787.

  • 140

    WenX.LiH.SunH.ZengA.LinR.ZhaoJ.et al (2020). MiR-455-3p Reduces Apoptosis and Alleviates Degeneration of Chondrocyte through Regulating PI3K/AKT Pathway. Life Sci.253, 117718. 10.1016/j.lfs.2020.117718

  • 141

    WengC.XuJ.WangQ.LuW.LiuZ. (2020). Efficacy and Safety of Duloxetine in Osteoarthritis or Chronic Low Back Pain: a Systematic Review and Meta-Analysis. Osteoarthritis Cartilage28, 721–734. 10.1016/j.joca.2020.03.001

  • 142

    WijnS. R. W.RoversM. M.van TienenT. G.HanninkG. (2020). Intra-articular Corticosteroid Injections Increase the Risk of Requiring Knee Arthroplasty. Bone Jt. J102-b, 586–592. 10.1302/0301-620X.102B5.BJJ-2019-1376.R1

  • 143

    WoodsS.BarterM. J.ElliottH. R.McGillivrayC. M.BirchM. A.ClarkI. M.et al (2019). miR-324-5p Is up Regulated in End-Stage Osteoarthritis and Regulates Indian Hedgehog Signalling by Differing Mechanisms in Human and Mouse. Matrix Biol.77, 87–100. 10.1016/j.matbio.2018.08.009

  • 144

    WuJ.MaL.WuL.JinQ. (2017). Wnt-β-catenin Signaling Pathway Inhibition by Sclerostin May Protect against Degradation in Healthy but Not Osteoarthritic Cartilage. Mol. Med. Rep.15, 2423–2432. 10.3892/mmr.2017.6278

  • 145

    WuX.WangY.XiaoY.CrawfordR.MaoX.PrasadamI. (2020). Extracellular Vesicles: Potential Role in Osteoarthritis Regenerative Medicine. J. Orthop. Translat21, 73–80. 10.1016/j.jot.2019.10.012

  • 146

    WuY.HongZ.XuW.ChenJ.WangQ.ChenJ.et al (2021). Circular RNA circPDE4D Protects against Osteoarthritis by Binding to miR-103a-3p and Regulating FGF18. Mol. Ther.29, 308–323. 10.1016/j.ymthe.2020.09.002

  • 147

    WuY.LuX.LiM.ZengJ.ZengJ.ShenB.et al (2019). Renin-angiotensin System in Osteoarthritis: A New Potential Therapy. Int. Immunopharmacol75, 105796. 10.1016/j.intimp.2019.105796

  • 148

    WuY.LuX.ShenB.ZengY. (2019). The Therapeutic Potential and Role of miRNA, lncRNA, and circRNA in Osteoarthritis. Curr. Gene Ther.19, 255–263. 10.2174/1566523219666190716092203

  • 149

    WuY.ZhangY.ZhangY.WangJ. J. (2017). CircRNA Hsa_circ_0005105 Upregulates NAMPT Expression and Promotes Chondrocyte Extracellular Matrix Degradation by Sponging miR-26a. Cel Biol Int41, 1283–1289. 10.1002/cbin.10761

  • 150

    WuZ.ShouL.WangJ.XuX. (2020). Identification of the Key Gene and Pathways Associated with Osteoarthritis via Single-Cell RNA Sequencing on Synovial Fibroblasts. Medicine (Baltimore)99, e21707. 10.1097/MD.0000000000021707

  • 151

    XiaoJ.WangR.ZhouW.CaiX.YeZ. (2021). Circular RNA CSNK1G1 Promotes the Progression of Osteoarthritis by Targeting the miR-4428/FUT2 axis. Int. J. Mol. Med.47, 232–242. 10.3892/ijmm.2020.4772

  • 152

    XiaoY.BaoY.TangL.WangL. (2019). LncRNA MIR4435-2HG Is Downregulated in Osteoarthritis and Regulates Chondrocyte Cell Proliferation and Apoptosis. J. Orthop. Surg. Res.14, 247. 10.1186/s13018-019-1278-7

  • 153

    XiaoY.YanX.YangY.MaX. (2019). Downregulation of Long Noncoding RNA HOTAIRM1 Variant 1 Contributes to Osteoarthritis via Regulating miR-125b/BMPR2 axis and Activating JNK/MAPK/ERK Pathway. Biomed. Pharmacother.109, 1569–1577. 10.1016/j.biopha.2018.10.181

  • 154

    XieF.LiuY. L.ChenX. Y.LiQ.ZhongJ.DaiB. Y.et al (2020). Role of MicroRNA, LncRNA, and Exosomes in the Progression of Osteoarthritis: A Review of Recent Literature. Orthop. Surg.12, 708–716. 10.1111/os.12690

  • 155

    XieY.ZinkleA.ChenL.MohammadiM. (2020). Fibroblast Growth Factor Signalling in Osteoarthritis and Cartilage Repair. Nat. Rev. Rheumatol.16, 547–564. 10.1038/s41584-020-0469-2

  • 156

    XuJ.XuY. (2017). The lncRNA MEG3 Downregulation Leads to Osteoarthritis Progression via miR-16/SMAD7 axis. Cell Biosci7, 69. 10.1186/s13578-017-0195-x

  • 157

    XuW.GaoP.ZhangY.PiaoL.DongD. (2019). microRNA-138 Induces Cell Survival and Reduces WNT/β-catenin Signaling of Osteoarthritis Chondrocytes through NEK2. IUBMB Life71, 1355–1366. 10.1002/iub.2050

  • 158

    XueH.TuY.MaT.WenT.YangT.XueL.et al (2019). miR-93-5p Attenuates IL-1β-induced Chondrocyte Apoptosis and Cartilage Degradation in Osteoarthritis Partially by Targeting TCF4. Bone123, 129–136. 10.1016/j.bone.2019.03.035

  • 159

    XueH.YuP.WangW. Z.NiuY. Y.LiX. (2020). The Reduced lncRNA NKILA Inhibited Proliferation and Promoted Apoptosis of Chondrocytes via miR-145/sp1/nf-Κb Signaling in Human Osteoarthritis. Eur. Rev. Med. Pharmacol. Sci.24, 535–548. 10.26355/eurrev_202001_20030

  • 160

    YangD. W.ZhangX.QianG. B.JiangM. J.WangP.WangK. Z. (2019). Downregulation of Long Noncoding RNA LOC101928134 Inhibits the Synovial Hyperplasia and Cartilage Destruction of Osteoarthritis Rats through the Activation of the Janus Kinase/signal Transducers and Activators of Transcription Signaling Pathway by Upregulating IFNA1. J. Cel Physiol234, 10523–10534. 10.1002/jcp.27730

  • 161

    YangM.YanX.YuanF. Z.YeJ.DuM. Z.MaoZ. M.et al (2021). MicroRNA-210-3p Promotes Chondrogenic Differentiation and Inhibits Adipogenic Differentiation Correlated with HIF-3α Signalling in Bone Marrow Mesenchymal Stem Cells. Biomed. Res. Int.2021, 6699910. 10.1155/2021/6699910

  • 162

    YangQ.LiX.ZhouY.FuW.WangJ.WeiQ. (2019). A LINC00341-Mediated Regulatory Pathway Supports Chondrocyte Survival and May Prevent Osteoarthritis Progression. J. Cel Biochem120, 10812–10820. 10.1002/jcb.28372

  • 163

    YangR. Z.ZhengH. L.XuW. N.ZhengX. F.LiB.JiangL. S.et al (2021). Vascular Endothelial Cell-Secreted Exosomes Facilitate Osteoarthritis Pathogenesis by Promoting Chondrocyte Apoptosis. Aging (Albany NY)13, 4647–4662. 10.18632/aging.202506

  • 164

    YangX.HeH.GaoQ.HeC. (2018). Pulsed Electromagnetic Field Improves Subchondral Bone Microstructure in Knee Osteoarthritis Rats through a Wnt/β-Catenin Signaling-Associated Mechanism. Bioelectromagnetics39, 89–97. 10.1002/bem.22106

  • 165

    YangY.WangY.JiaH.LiB.XingD.LiJ. J. (2020). MicroRNA-1 Modulates Chondrocyte Phenotype by Regulating FZD7 of Wnt/β-Catenin Signaling Pathway. Cartilage. [Epub ahead of print]. 10.1177/1947603520973255

  • 166

    YangZ.TangY.LuH.ShiB.YeY.XuG.et al (2018). Long Non-coding RNA Reprogramming (lncRNA-ROR) Regulates Cell Apoptosis and Autophagy in Chondrocytes. J. Cel Biochem119, 8432–8440. 10.1002/jcb.27057

  • 167

    Yaşar ŞirinD.Yılmazİ.İsyarM.ÖznamK.MahiroğullarıM. (2017). Does Leukocyte-Poor or Leukocyte-Rich Platelet-Rich Plasma Applied with Biopolymers Have Superiority to Conventional Platelet-Rich Plasma Applications on Chondrocyte Proliferation?. Eklem Hastalik Cerrahisi28, 142–151. 10.5606/ehc.2017.55186

  • 168

    YeD.JianW.FengJ.LiaoX. (2018). Role of Long Noncoding RNA ZFAS1 in Proliferation, Apoptosis and Migration of Chondrocytes in Osteoarthritis. Biomed. Pharmacother.104, 825–831. 10.1016/j.biopha.2018.04.124

  • 169

    YingH.WangY.GaoZ.ZhangQ. (2019). Long Non-coding RNA Activated by Transforming Growth Factor Beta Alleviates Lipopolysaccharide-Induced Inflammatory Injury via Regulating microRNA-223 in ATDC5 Cells. Int. Immunopharmacol69, 313–320. 10.1016/j.intimp.2019.01.056

  • 170

    YoshikoY.MinamizakiT. (2020). Emerging Roles of microRNAs as Extracellular Vesicle Cargo Secreted from Osteoblasts. J. Oral Biosci.62, 228–234. 10.1016/j.job.2020.05.006

  • 171

    YuC.ShiD.LiZ.WanG.ShiX. (2019). Long Noncoding RNA CHRF Exacerbates IL-6-induced Inflammatory Damages by Downregulating microRNA-146a in ATDC5 Cells. J. Cel Physiol234, 21851–21859. 10.1002/jcp.28749

  • 172

    YuF.XieC.SunJ.FengH.HuangX. (2018). Circular RNA Expression Profiles in Synovial Fluid: a Promising New Class of Diagnostic Biomarkers for Osteoarthritis. Int. J. Clin. Exp. Pathol.11, 1338–1346.

  • 173

    YuL.LiuS.ZhaoZ.XiaL.ZhangH.LouJ.et al (2017). Extracorporeal Shock Wave Rebuilt Subchondral Bone In Vivo and Activated Wnt5a/Ca2+ Signaling In Vitro. Biomed. Res. Int.2017, 1404650. 10.1155/2017/1404650

  • 174

    ZhaiX.MengR.LiH.LiJ.JingL.QinL.et al (2017). miR-181a Modulates Chondrocyte Apoptosis by Targeting Glycerol-3-Phosphate Dehydrogenase 1-Like Protein (GPD1L) in Osteoarthritis. Med. Sci. Monit.23, 1224–1231. 10.12659/msm.899228

  • 175

    ZhangG.WuY.XuD.YanX. (2016). Long Noncoding RNA UFC1 Promotes Proliferation of Chondrocyte in Osteoarthritis by Acting as a Sponge for miR-34a. DNA Cel Biol35, 691–695. 10.1089/dna.2016.3397

  • 176

    ZhangL.ZhangP.SunX.ZhouL.ZhaoJ. (2018). Long Non-coding RNA DANCR Regulates Proliferation and Apoptosis of Chondrocytes in Osteoarthritis via miR-216a-5p-JAK2-STAT3 axis. Biosci. Rep.38. 10.1042/BSR20181228

  • 177

    ZhangW.ChengP.HuW.YinW.GuoF.ChenA.et al (2018). Inhibition of microRNA-384-5p Alleviates Osteoarthritis through its Effects on Inhibiting Apoptosis of Cartilage Cells via the NF-Κb Signaling Pathway by Targeting SOX9. Cancer Gene Ther.25, 326–338. 10.1038/s41417-018-0029-y

  • 178

    ZhangW.HuC.ZhangC.LuoC.ZhongB.YuX. (2021). MiRNA-132 Regulates the Development of Osteoarthritis in Correlation with the Modulation of PTEN/PI3K/AKT Signaling. BMC Geriatr.21, 175. 10.1186/s12877-021-02046-8

  • 179

    ZhangW.ZhangC.HuC.LuoC.ZhongB.YuX. (2020). Circular RNA-CDR1as Acts as the Sponge of microRNA-641 to Promote Osteoarthritis Progression. J. Inflamm. (Lond)17, 8. 10.1186/s12950-020-0234-y

  • 180

    ZhangW.QiL.ChenR.HeJ.LiuZ.WangW.et al (2021). Circular RNAs in Osteoarthritis: Indispensable Regulators and Novel Strategies in Clinical Implications. Arthritis Res. Ther.23, 23. 10.1186/s13075-021-02420-2

  • 181

    ZhangY.WangF.ChenG.HeR.YangL. (2019). LncRNA MALAT1 Promotes Osteoarthritis by Modulating miR-150-5p/AKT3 axis. Cel Biosci9, 54. 10.1186/s13578-019-0302-2

  • 182

    ZhangZ.MeiY.FengM.WangC.YangP.TianR. (2021). The Relationship between Common Variants in the DPEP1 Gene and the Susceptibility and Clinical Severity of Osteoarthritis. Int. J. Rheum. Dis.24 (9), 1192–1199. 10.1111/1756-185x.14182

  • 183

    ZhaoC. (2021). Identifying the Hub Gene and Immune Infiltration of Osteoarthritis by Bioinformatical Methods. Clin. Rheumatol.40, 1027–1037. 10.1007/s10067-020-05311-0

  • 184

    ZhaoJ.HuangH.LiangG.ZengL. F.YangW.LiuJ. (2020). Effects and Safety of the Combination of Platelet-Riched Plasma (PRP) and Hyaluronic Acid (HA) in the Treatment of Knee Osteoarthritis: a Systematic Review and Meta-Analysis. BMC Musculoskelet. Disord.21, 224. 10.1186/s12891-020-03262-w

  • 185

    ZhaoT.MaC.XieB.ZhaoB.WangW.LiuJ. (2020). Evaluation of Common Variants in the AKNA Gene and Susceptibility to Knee Osteoarthritis Among the Han Chinese. Genet. Test. Mol. Biomarkers24, 425–430. 10.1089/gtmb.2020.0014

  • 186

    ZhaoX.LiH.WangL. (2019). MicroRNA-107 Regulates Autophagy and Apoptosis of Osteoarthritis Chondrocytes by Targeting TRAF3. Int. Immunopharmacol71, 181–187. 10.1016/j.intimp.2019.03.005

  • 187

    ZhaoX.MengF.HuS.YangZ.HuangH.PangR.et al (2020). The Synovium Attenuates Cartilage Degeneration in KOA through Activation of the Smad2/3-Runx1 Cascade and Chondrogenesis-Related miRNAs. Mol. Ther. Nucleic Acids22, 832–845. 10.1016/j.omtn.2020.10.004

  • 188

    ZhengL.WangY.QiuP.XiaC.FangY.MeiS.et al (2019). Primary Chondrocyte Exosomes Mediate Osteoarthritis Progression by Regulating Mitochondrion and Immune Reactivity. Nanomedicine (Lond)14, 3193–3212. 10.2217/nnm-2018-0498

  • 189

    ZhengX.ZhaoF. C.PangY.LiD. Y.YaoS. C.SunS. S.et al (2017). Downregulation of miR-221-3p Contributes to IL-1β-induced Cartilage Degradation by Directly Targeting the SDF1/CXCR4 Signaling Pathway. J. Mol. Med. (Berl)95, 615–627. 10.1007/s00109-017-1516-6

  • 190

    ZhongG.LongH.MaS.ShunhanY.LiJ.YaoJ. (2019). miRNA-335-5p Relieves Chondrocyte Inflammation by Activating Autophagy in Osteoarthritis. Life Sci.226, 164–172. 10.1016/j.lfs.2019.03.071

  • 191

    ZhongW.LiX.PathakJ. L.ChenL.CaoW.ZhuM.et al (2020). Dicalcium Silicate Microparticles Modulate the Differential Expression of circRNAs and mRNAs in BMSCs and Promote Osteogenesis via Circ_1983-miR-6931-Gas7 Interaction. Biomater. Sci.8, 3664–3677. 10.1039/d0bm00459f

  • 192

    ZhouJ.LiC.YuA.JieS.DuX.LiuT.et al (2019). Bioinformatics Analysis of Differentially Expressed Genes Involved in Human Developmental Chondrogenesis. Medicine (Baltimore)98, e16240. 10.1097/MD.0000000000016240

  • 193

    ZhouQ. F.CaiY. Z.LinX. J. (2020). The Dual Character of Exosomes in Osteoarthritis: Antagonists and Therapeutic Agents. Acta Biomater.105, 15–25. 10.1016/j.actbio.2020.01.040

  • 194

    ZhouX.JiangL.FanG.YangH.WuL.HuangY.et al (2019). Role of the ciRS-7/miR-7 axis in the Regulation of Proliferation, Apoptosis and Inflammation of Chondrocytes Induced by IL-1β. Int. Immunopharmacol71, 233–240. 10.1016/j.intimp.2019.03.037

  • 195

    ZhouX.JiangL.ZhangY.ZhangJ.ZhouD.WuL.et al (2019). Genetic Variation of Aggrecanase-2 (ADAMTS5) in Susceptibility to Osteoarthritis. Braz. J. Med. Biol. Res.52, e8109. 10.1590/1414-431X20188109

  • 196

    ZhouZ. B.DuD.HuangG. X.ChenA.ZhuL. (2018). Circular RNA Atp9b, a Competing Endogenous RNA, Regulates the Progression of Osteoarthritis by Targeting miR-138-5p. Gene646, 203–209. 10.1016/j.gene.2017.12.064

  • 197

    ZhouZ. B.HuangG. X.FuQ.HanB.LuJ. J.ChenA. M.et al (2019). circRNA.33186 Contributes to the Pathogenesis of Osteoarthritis by Sponging miR-127-5p. Mol. Ther.27, 531–541. 10.1016/j.ymthe.2019.01.006

  • 198

    ZhuH.HuY.WangC.ZhangX.HeD. (2020). CircGCN1L1 Promotes Synoviocyte Proliferation and Chondrocyte Apoptosis by Targeting miR-330-3p and TNF-α in TMJ Osteoarthritis. Cel Death Dis11, 284. 10.1038/s41419-020-2447-7

  • 199

    ZhuJ. K.HeT. D.WeiZ. X.WangY. M. (2018). LncRNA FAS-AS1 Promotes the Degradation of Extracellular Matrix of Cartilage in Osteoarthritis. Eur. Rev. Med. Pharmacol. Sci.22, 2966–2972. 10.26355/eurrev_201805_15051

  • 200

    ZhuY. J.JiangD. M. (2019). LncRNA PART1 Modulates Chondrocyte Proliferation, Apoptosis, and Extracellular Matrix Degradation in Osteoarthritis via Regulating miR-373-3p/SOX4 axis. Eur. Rev. Med. Pharmacol. Sci.23, 8175–8185. 10.26355/eurrev_201910_19124

Summary

Keywords

osteoarthritis, DNA, RNA, exosomes, platelet-rich plasma, protein, gene

Citation

Deng J, Zong Z, Su Z, Chen H, Huang J, Niu Y, Zhong H and Wei B (2021) Recent Advances in Pharmacological Intervention of Osteoarthritis: A Biological Aspect. Front. Pharmacol. 12:772678. doi: 10.3389/fphar.2021.772678

Received

08 September 2021

Accepted

04 October 2021

Published

23 November 2021

Volume

12 - 2021

Edited by

Liangliang Xu, Guangzhou University of Chinese Medicine, China

Reviewed by

Wenxiang Cheng, Shenzhen Institutes of Advanced Technology, China

Liming Zhao, Stanford University, United States

Updates

Copyright

© 2021 Deng, Zong, Su, Chen, Huang, Niu, Zhong and Wei.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Huan Zhong, ; Bo Wei,

This article was submitted to Integrative and Regenerative Pharmacology, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics